Neurocrine Biosciences Presents INGREZZA Capsules Interim Da

SAN DIEGO - Neurocrine Biosciences, Inc. today announced interim results from the ongoing open-label KINECT-HD2 study about INGREZZA capsules when used for the long-term treatment of adults with...

Related Keywords

Phoenix , Arizona , United States , Neurocrine Biosciences , Aimee White , Neurocrine Bioscience , Eiryw Roberts , Exchange Commission , Huntington Disease Health Index , Clinical Research Inc , Drug Administration , Nasdaq , Huntington Study Group , A Wearable Movement Sensor Substudy , Neurocrine Biosciences Inc , Annual Meeting , Study Group , Chief Medical Officer , Chorea Associated With Huntington , Interim Results From , Long Term Open Label Study , Wearable Movement Sensor Substudy , Disease Health Index , Measuring Changes , Disease Burden , Valbenazine During , Minimal Clinically Important Difference , Maximal Chorea Score , Chorea Severity , Treatment Comparison , Valbenazine With Deutetrabenazine , Total Maximal Chorea Score , Chorea Associated , Unified Huntington , Disease Rating Scale , Total Maximal Chorea , Clinical Global Impression , Patient Global Impression , News Publishing , Markets ,